Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albinterferon Alfa-2b Plus Ribavirin in Genotype 2/3 Chronic Hepatitis C
NCT00759200Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2008
- Primary completion
- Dec 2010
- Modality
- Fc-Fusion Proteins
- Countries
- 12
01
Overview
A Phase 2 trial of albinterferon alfa-2b in hepatitis C (HCV), sponsored by Novartis. Started Oct 2008; status: completed.
02
Drugs
albinterferon alfa-2b
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00759200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00759200.